UY26982A1 - Derivados de indirubina que contienen azufre, su preparación y uso - Google Patents

Derivados de indirubina que contienen azufre, su preparación y uso

Info

Publication number
UY26982A1
UY26982A1 UY26982A UY26982A UY26982A1 UY 26982 A1 UY26982 A1 UY 26982A1 UY 26982 A UY26982 A UY 26982A UY 26982 A UY26982 A UY 26982A UY 26982 A1 UY26982 A1 UY 26982A1
Authority
UY
Uruguay
Prior art keywords
diseases
preparation
disease
caused
containing sulfur
Prior art date
Application number
UY26982A
Other languages
English (en)
Inventor
Rolf Jautelat
Olaf Prien
Andreas Steinmeyer
Gerhard Siemeister
Martina Schafer
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY26982A1 publication Critical patent/UY26982A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen derivados de sulfanil-indirubina, su preparación y los productos intermedios para su preparación, así como su uso como medicamento para el tratamiento de cánceres tales como tumores sólidos y leucemia, enfermedades autoinmunes como psoriasis, alopecia y esclerosis múltiple, enfermedades cardiovasculares tales como estenosis, arteriosclerosis y restenosis, enfermedades infecciosas como por ejemplo provocadas por parásitos unicelulares, o por hongos, enfermedades nefrológicas, enfermedades neurodegenerativas crónicas, como enfermedad de Huntigton, esclerosis lateral amiotrófica, Parkinson y Alzheimer, enfermedades neurodegenerativas agudas, como isquemias cerebrales y traumas neuronales, infecciones virales, como infecciones de citomegalovirus, herpes, hepatitis B y C, y enfermedades provocadas por HIV.
UY26982A 2000-10-24 2001-10-23 Derivados de indirubina que contienen azufre, su preparación y uso UY26982A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10053474A DE10053474A1 (de) 2000-10-24 2000-10-24 Schwefelhaltige Indirubinderivate, deren Herstellung und Verwendung

Publications (1)

Publication Number Publication Date
UY26982A1 true UY26982A1 (es) 2002-06-20

Family

ID=7661370

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26982A UY26982A1 (es) 2000-10-24 2001-10-23 Derivados de indirubina que contienen azufre, su preparación y uso

Country Status (6)

Country Link
US (1) US20020107404A1 (es)
AU (1) AU2002210548A1 (es)
DE (1) DE10053474A1 (es)
PE (1) PE20030208A1 (es)
UY (1) UY26982A1 (es)
WO (1) WO2002034717A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
DE10114138C2 (de) * 2001-03-16 2003-03-27 Schering Ag Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit
DE10125763A1 (de) * 2001-05-17 2002-11-28 Schering Ag Verwendung selektiver Indirubinderivate als VEGF-R Inhibitoren
US7582670B2 (en) 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR100588803B1 (ko) * 2004-01-27 2006-06-12 학교법인조선대학교 암세포주에 항암활성을 지닌 인디루빈 유도체
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2615105A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007076372A2 (en) * 2005-12-23 2007-07-05 University Of Rochester Treatment of neuroaids using inhibitors of glycogen synthase kinase (gsk)-3
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CN103391773A (zh) 2010-09-27 2013-11-13 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
CN103333161B (zh) * 2013-05-28 2015-09-30 滁州市洛达生物科技有限公司 1’-氧代靛玉红的制备和用途
US11083755B2 (en) 2015-01-08 2021-08-10 The Board Of Trustees Of The Leland Stanford Junior University Factors and cells that provide for induction of bone, bone marrow, and cartilage
CN108486186A (zh) * 2018-03-20 2018-09-04 合肥皖为生物科技有限公司 一种氧化酶制备具有抗肿瘤活性的靛玉红的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2333661A1 (en) * 1998-05-29 1999-12-09 Cnrs (Centre National De Recherche Scientifique) France Innovation Scien Tifique Et Transfernt Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
EP0966963A1 (en) * 1998-05-29 1999-12-29 Gerhard Prof. Dr. Eisenbrand Use of indigoid bisindole derivatives as CDK1 inhibitors
CA2369670A1 (en) * 1999-04-12 2000-10-19 Gerhard Eisenbrand Indigoid bisindole derivatives

Also Published As

Publication number Publication date
DE10053474A1 (de) 2002-05-02
US20020107404A1 (en) 2002-08-08
WO2002034717A1 (de) 2002-05-02
PE20030208A1 (es) 2003-04-03
AU2002210548A1 (en) 2002-05-06

Similar Documents

Publication Publication Date Title
UY26982A1 (es) Derivados de indirubina que contienen azufre, su preparación y uso
USD988218S1 (en) Vehicle instrument panel
USD908070S1 (en) Wheel
USD895513S1 (en) Wheel
USD904957S1 (en) Wheel
PT1387840E (pt) 3,5-diamino-1,2,4-triazoles como inibidoras cinases
BR0017030A (pt) Derivados de tiazolilamida
USD901592S1 (en) Vehicle-mounted sign
USD922295S1 (en) Wheel
USD924973S1 (en) Vehicle-mounted sign
BR0307819A (pt) Derivados de pirazol tricìclicos, processo para preparação dos mesmos como agentes antitumorais
ES2099758T3 (es) Procedimiento para preparar catalizadores para polimerizacion por adicion mediante oxidacion del nucleo metalico.
USD865618S1 (en) Wheel
USD924971S1 (en) Vehicle-mounted sign
USD927737S1 (en) Auxiliary vehicle light
WO2002074742A3 (de) Cdk-inhibitorische indirubinderivate mit erhöhter löslichkeit
SV1998000023A (es) Arilsulfonamidas y analogos ref. lea 32316-sv
ATE151776T1 (de) Cytotoxische und antivirale verbindung
UY27293A1 (es) Uso de derivados selectivos de indirrubina como inhibidores de vegr-r
WO2004043402A3 (en) Modified nucleosides as antiviral agents
UY27043A1 (es) Derivados de indirubina aril-sustituidos, su preparación y uso
IT7825578A0 (it) Processo per la produzione di nuovi cromone-derivati nonche' loro impiego come materiali protettivi delle piante.
IT1078784B (it) Processo per la produzione di triazin 2.4 dioni nonche loro impiego come insetticidi
TH62087EX (th) พวงมาลัย
ITTV950007A1 (it) Struttura di casco protettivo, particolarmente per il ciclismo

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126